EXTON, Pa., April 03, 2019 (GLOBE NEWSWIRE) -- Aspire Bariatrics, Inc. (“Aspire”), a commercial-stage medical device company, announced today that the American Society of the Metabolic and Bariatric Surgeons (“ASMBS”) has endorsed the AspireAssist as one of the procedures and devices for metabolic and bariatric treatment. Receipt of endorsement of a device or procedure means that a device or procedure may be used in medical centers accredited by the Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program (“MBSAQIP”) without having to obtain Institutional Review Board (IRB) approval.
“We are grateful to the ASMBS for their hard work and diligence in their review of all the clinical data on the AspireAssist in reaching a positive endorsement decision,” said Kathy Crothall, PhD, President & CEO of Aspire Bariatrics. “Endorsement of the AspireAssist is a huge milestone for Aspire and will help make AspireAssist therapy move available to patients with patients with body mass indexes (BMI) 35 -55 who decline bariatric surgery or are not candidates for surgery.”
“The AspireAssist procedure is the first endoscopic procedure endorsed by the ASMBS for patients with BMIs in excess of 40 or for patients who need a long-duration treatment. Endorsement of the AspireAssist by the ASMBS expands the armamentarium for treatment of obesity. There is a huge unmet need to provide safe and effective treatment alternatives to patients with obesity who either do not want or cannot have bariatric surgery,” said Carson Liu, MD, FACS of SkyLex Health in Santa Monica, CA.
About Aspire Bariatrics, Inc.
Aspire Bariatrics is a commercial-stage medical device company with a minimally-invasive, endoscopic device, the AspireAssist®, to treat obesity. In June 2016, the Company received premarket approval (PMA) from the FDA. The AspireAssist® is intended to assist in weight reduction of obese patients. It is indicated for use in adults aged 22 or older with a Body Mass Index (BMI) of 35.0-55.0 kg/m2 who have failed to achieve and maintain weight loss with non-surgical weight loss therapy. The AspireAssist is intended for a long-term duration of use in conjunction with lifestyle therapy and continuous medical monitoring.
Contact for Investors and Media
Kathy Crothall, PhD
President and CEO
(610) 590-1568
kathy.crothall@aspirebariatrics.com